Last reviewed · How we verify
ammonia
At a glance
| Generic name | ammonia |
|---|---|
| Sponsor | Feinstein |
| Drug class | Radioactive Diagnostic Agent [EPC] |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Approved indications
- Acne vulgaris
- Disorder of keratinization
- Pityriasis simplex
- Psoriasis
- Seborrheic dermatitis
Common side effects
Key clinical trials
- Clinical Laboratory Evaluation of Chronic Autonomic Failure
- Safety of PET MPI Using the CRCHUM N-13 Ammonia (PHASE4)
- Total-body 13N-NH3 PET/CT to Study the Blood Perfusion in Severe AS Patients Pre- and Post-TAVR in Whole Body
- Evaluation of the Outcome of Fecal Microbiota Transplantation (PHASE1,PHASE2)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 (PHASE4)
- Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2 (PHASE4)
- A Study to Determine Number of Patients Who Develop High Ammonia Levels After Receiving Recombinant Erwinia Asparaginase
- Clinical and Cost-Effectiveness of Silver Diamine Fluoride and Silver Fluoride, With or Without Application of LED, in Arresting Incipient Permament Molar Caries (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ammonia CI brief — competitive landscape report
- ammonia updates RSS · CI watch RSS
- Feinstein portfolio CI